A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study With a Separate Open-label Cohort to Evaluate the Efficacy and Safety of Brenipatide as Adjunctive Treatment to Transmucosal Buprenorphine With or Without Naloxone in Early Recovery of Participants With Opioid Use Disorder (RENEW-Op-1)
Latest Information Update: 10 Mar 2026
At a glance
- Drugs Brenipatide (Primary) ; Buprenorphine (Primary)
- Indications Opioid-related disorders
- Focus Therapeutic Use
- Acronyms RENEW-Op-1
- Sponsors Eli Lilly and Company
Most Recent Events
- 04 Mar 2026 Planned End Date changed from 1 Mar 2028 to 1 Feb 2028.
- 04 Mar 2026 Planned primary completion date changed from 1 Mar 2028 to 1 Aug 2027.
- 04 Mar 2026 Status changed from not yet recruiting to recruiting.